Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients

British Journal of Haematology

Volumn 101, Issue 3, 1998, Pages 413-415

  Töndury, Petrign ^a   Zimmermann, Arthur ^a   Nielsen, Peter ^b   Hirt, Andreas ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chronic active hepatitis; Hepatic fibrosis; Hepatitis C; Long term L1 deferiprone

Indexed keywords

ALPHA INTERFERON; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; RIBAVIRIN;

ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; LIVER BIOPSY; LIVER FIBROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT FAILURE;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHRONIC DISEASE; FERRITINS; HEPATITIS C; HUMANS; IRON CHELATING AGENTS; LIVER CIRRHOSIS; LONG-TERM CARE; PYRIDONES;

EID: 0031859182     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00725.x     Document Type: Article

References (11)

1. Bacon, B.R. & Britton, R.S. (1990) The pathology of hepatic iron overload: a free radical mediated process? Hepatology, 211, 127-130.
2. Brillanti, S., Garson, J., Foli, M., Whitby, K., Deaville, R., Masci, C., Miglioli, M. & Luigi, B. (1994) A pilot study of combination therapy with ribavirine plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology, 107, 812-817.
3. Brittenham, G.M., Farrell, D.E., Harris, J.W., Feldman, E.S., Danish, E.H., Mui, W.A., Tripp, J.H. & Bellon, E.M. (1982) Magnetic susceptibility measurement of human iron stores. New England Journal of Medicine, 307, 1671-1675.
4. Cohen, A.R., for the LA-02 study group (1997) A multi-center safety trial of the oral iron chelator deferiprone. Abstract 273, 6th International Conference on Thalassaemia and the Haemoglobinopathies.
5. Lai, M.Y., Kao, J.H., Yang, P.M., Wang, J.T., Chen, P.J., Chan, K.W., Chu, J.S. & Chen, D.S. (1996) Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology, 111, 1307-1312.
6. Nielsen, P., Fischer, R., Engelhardt, R., Töndury, P., Gabbe, E.E. & Janka, G.E. (1995) Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. British Journal of Haematology, 91, 827-840.
7. Olivieri, N.F., for the Toronto Iron Chelation Group (1996) Long-term follow-up of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1). Blood (abstract supplement). 88, 310a.
8. Olivieri, N.F., Nathan, D.G., MacMillan, J.H., Wayne, A.D., Martin, M., McGee, A., Koren, G., Liu, P.P. & Cohen, A.R. (1994) Survival of medically treated patients with homozygous β-thalassemia. New England Journal of Medicine, 331, 574-580.
9. Schmid, M., Flury, R., Biihler, H., Havelka, J., Grob, P.J. & Heitz, P.U. (1994) Chronic viral hepatitis B and C: an argument against the conventional classification of chronic hepatitis. Virchows Archives. 425, 221-228.
10. Van Deursen, C., de Metz, M., Koudstaal, J. & Brombacher, P. (1988) Accumulation of iron and iron compounds in liver tissue: a comparative study of the histological and chemical estimation of liver iron. Journal of Clinical Chemistry and Clinical Biochemistry, 26, 617-622.
11. Zhao, M., Laissue, J.A. & Zimmermann, A. (1997) Hepatocyte apoptosis in hepatic iron overload diseases. Histology and Histopathology, 12, 367-364.